基层医学论坛
基層醫學論罈
기층의학론단
PUBLIC MEDICAL FORUM MAGAZINE
2013年
16期
2047-2048
,共2页
李文格%杜怀文%郑民洁%陈强%努尔比亚
李文格%杜懷文%鄭民潔%陳彊%努爾比亞
리문격%두부문%정민길%진강%노이비아
舒张性心力衰竭%厄贝沙坦氢氯噻嗪%螺内酯%BNP
舒張性心力衰竭%阨貝沙坦氫氯噻嗪%螺內酯%BNP
서장성심력쇠갈%액패사탄경록새진%라내지%BNP
Diastolic heart failure%Irbesartan and Hydrochlorothiazide%Spironolactone%BNP
目的探讨厄贝沙坦氢氯噻嗪联合螺内酯治疗舒张性心力衰竭(DHF)的效果及安全性.方法120例DHF患者随机分为常规组与治疗组,常规组给予常规治疗,治疗组在常规基础上加用厄贝沙坦氢氯噻嗪联合螺内酯治疗.通过6 min步行试验和超声心动图指标舒张早期最大血流峰值速度(E峰)、舒张末期最大血流峰值速度(A峰)、E/A比值变化,监测血浆脑钠肽(BNP),比较2组临床疗效.结果2组治疗前后比较左室舒张功能指标E峰、A峰、E/A比值、6 min步行试验、BNP改变均优于治疗前(P<0.01),并且治疗后对比治疗组优于常规组(P<0.01).结论厄贝沙坦氢氯噻嗪联合螺内酯治疗DHF疗效显著,安全性好,值得临床推广.
目的探討阨貝沙坦氫氯噻嗪聯閤螺內酯治療舒張性心力衰竭(DHF)的效果及安全性.方法120例DHF患者隨機分為常規組與治療組,常規組給予常規治療,治療組在常規基礎上加用阨貝沙坦氫氯噻嗪聯閤螺內酯治療.通過6 min步行試驗和超聲心動圖指標舒張早期最大血流峰值速度(E峰)、舒張末期最大血流峰值速度(A峰)、E/A比值變化,鑑測血漿腦鈉肽(BNP),比較2組臨床療效.結果2組治療前後比較左室舒張功能指標E峰、A峰、E/A比值、6 min步行試驗、BNP改變均優于治療前(P<0.01),併且治療後對比治療組優于常規組(P<0.01).結論阨貝沙坦氫氯噻嗪聯閤螺內酯治療DHF療效顯著,安全性好,值得臨床推廣.
목적탐토액패사탄경록새진연합라내지치료서장성심력쇠갈(DHF)적효과급안전성.방법120례DHF환자수궤분위상규조여치료조,상규조급여상규치료,치료조재상규기출상가용액패사탄경록새진연합라내지치료.통과6 min보행시험화초성심동도지표서장조기최대혈류봉치속도(E봉)、서장말기최대혈류봉치속도(A봉)、E/A비치변화,감측혈장뇌납태(BNP),비교2조림상료효.결과2조치료전후비교좌실서장공능지표E봉、A봉、E/A비치、6 min보행시험、BNP개변균우우치료전(P<0.01),병차치료후대비치료조우우상규조(P<0.01).결론액패사탄경록새진연합라내지치료DHF료효현저,안전성호,치득림상추엄.
Objective To explone the therapeutic effect and safety of combination of Irbesartan and Hydrochlorothiazide and sprionolactone on diastolic heart failure (DHF). Methods 120 patients with DHF were randomly divided into two groups routine treatment group (control group)and valsartan group (experimental group) which receive treatment of Irbesartan combination Spironolactone on the basis of routin treatment. The changing of the levels of plasma brain natriuretic peptide (BNP)and the indexes of echocardiogram and 6 minute walk test(6-MWT) were observed after six months treatment and made comparison. Results The levels of BNP of both groups decreased obviously (P<0.05),the ratio of left ventricular diastolic function A peak,E peak,E/A raised singnificantly(P<0.05), the 6-MWT also have significant increased in two groups (P<0.05),the results of the experimental group improved significantly (P<0.05),and there were statistic differences in comparison with those of the control group. Conclusion Irbesartan and Spironolactone in the treatment of left ventricular diastolic heart failure (DHF)are effective and safety, which deserve clinical promotion.